superadmin-base

First Made-in-Singapore Antibody-Drug Conjugate (ADC) Approved to Enter Clinical Trials

Approval has been obtained from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human trial for EBC-129 in patients with solid tumours EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) that is entering clinical development. It is able to selectively target cancer cells across a range of solid tumours. The ADC and the …

First Made-in-Singapore Antibody-Drug Conjugate (ADC) Approved to Enter Clinical Trials Read More »

XtalPi and EDDC collaborate in AI-empowered drug discovery program for Non-Small Cell Lung Cancer

XtalPi joins hands with Singapore’s national platform for drug discovery and development to discover more effective treatment options for cancer patients worldwide. In this collaboration, XtalPi will leverage its quantum physics and AI-driven platform, while EDDC provides valuable insight and data on the novel NSCLC target, to accelerate the drug discovery process and propel the …

XtalPi and EDDC collaborate in AI-empowered drug discovery program for Non-Small Cell Lung Cancer Read More »

Computational Chemistry: Virtual screening and drug discovery

Virtual screening involves the use of in silico methods to screen for potential small molecule binders of a target protein. This process usually starts with computationally docking a virtual library of chemical compounds to assess how the compounds interact with a defined binding site on the target protein. This is followed by scoring to predict …

Computational Chemistry: Virtual screening and drug discovery Read More »

STDR Roadshow for September 2022 Grant Call

STDR Roadshow for September 2022 Grant Call Calling all fellow drug hunters! Singapore Therapeutics Development Review’s (STDR) September grant call for Pre-Pilot Streams 1 & 2 will launch on 12 September 2022! There will also be a roadshow on 8 September at Fusionopolis, starting at 10.30am. Consultation sessions are available during the roadshow and can …

STDR Roadshow for September 2022 Grant Call Read More »

Minister for Trade and Industry, Mr Gan Kim Yong, visits EDDC

Minister for Trade and Industry, Mr Gan Kim Yong, creating an entry on the computer to insert a 384-well plate into the compound store at EDDC’s High Throughput Screening (HTS) facility.On 19 August 2022, Experimental Drug Development Centre (EDDC) hosted a visit by Minister for Trade and Industry, Mr Gan Kim Yong. This visit was …

Minister for Trade and Industry, Mr Gan Kim Yong, visits EDDC Read More »

2nd Minister of Ministry of Trade and Industry, Gan Kim Yong, visits EDDC

2nd Minister of Ministry of Trade and Industry, Mr Gan Kim Yong, visits EDDCMinister for Trade and Industry, Mr Gan Kim Yong, creating an entry on the computer to insert a 384-well plate into the compound store at EDDC’s High Throughput Screening (HTS) facility.On 19 August 2022, Experimental Drug Development Centre (EDDC) hosted a visit …

2nd Minister of Ministry of Trade and Industry, Gan Kim Yong, visits EDDC Read More »

SGInnovate webinar series: Advancing the science of Drug Discovery

SGInnovate webinar series: Advancing the Science of Drug DiscoveryOur colleague, Vishal Pendharkar, will be presenting at this event too!For the researchers who are trying to weigh out the pros and cons of using 𝘐𝘯 𝘝π˜ͺ𝘡𝘳𝘰 and 𝘐𝘯 𝘝π˜ͺ𝘷𝘰 models for drug discovery – this should be of interest to you!

Compounds against Tuberculosis developed by EDDC and NTU out-licensed to Neuro-Horizon Pharma

The World Health Organisation1 estimates that over 1.5 million people die from tuberculosis (TB) worldwide, making it the second leading infectious disease killer after COVID-19. Caused by the bacterium Mycobacterium tuberculosis, TB is an infectious disease that has plagued humankind for more than 70,000 years2, with an estimated 10 million new cases of TB annually. …

Compounds against Tuberculosis developed by EDDC and NTU out-licensed to Neuro-Horizon Pharma Read More »